MARKET

SIOX

SIOX

Sio Gene Therapies Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2900
-0.0033
-1.13%
After Hours: 0.2992 +0.0092 +3.17% 19:42 05/26 EDT
OPEN
0.2875
PREV CLOSE
0.2933
HIGH
0.3088
LOW
0.2800
VOLUME
1.30M
TURNOVER
0
52 WEEK HIGH
2.950
52 WEEK LOW
0.2303
MARKET CAP
21.37M
P/E (TTM)
-0.3405
1D
5D
1M
3M
1Y
5Y
We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 3d ago
Mid-Afternoon Market Update: Nasdaq Jumps 400 Points; Sio Gene Therapies Shares Plummet
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining more than 400 points on Thursday.
Benzinga · 04/28 19:17
Mid-Day Market Update: Teladoc Health Drops Following Q1 Results; Swvl Holdings Shares Jump
U.S. stocks traded higher through trading with the Dow Jones gaining more than 100 points on Thursday.
Benzinga · 04/28 16:07
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
 
Benzinga · 04/28 14:09
Sio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge
Benzinga · 04/28 12:56
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 04/28 12:52
28 Stocks Moving in Thursday's Pre-Market Session
Gainers T Stamp Inc. (NASDAQ: IDAI) shares rose 103.3% to $4.27 in pre-market trading after gaining over 8% on Wednesday. Trust Stamp recently posted Q4 net sales of $2.1 million.
Benzinga · 04/28 10:30
--Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80
MT Newswires · 04/28 09:17
More
No Data
Learn about the latest financial forecast of SIOX. Analyze the recent business situations of Sio Gene Therapies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
0.00%Buy
33.33%Hold
33.33%Under-perform
0.00%Sell
Analyst Price Target
The average SIOX stock price target is 2.900 with a high estimate of 5.00 and a low estimate of 0.8000.
High5.00
Average2.900
Low0.8000
Current 0.2951
EPS
Actual
Estimate
-0.28-0.21-0.14-0.07
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 62
Institutional Holdings: 20.20M
% Owned: 27.41%
Shares Outstanding: 73.71M
TypeInstitutionsShares
Increased
7
360.00K
New
4
11.54K
Decreased
17
1.01M
Sold Out
11
2.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.05%
Pharmaceuticals & Medical Research
+0.29%
Key Executives
Chairman/Director
Frank Torti
Chief Executive Officer/Director
Pavan Cheruvu
Chief Financial Officer/Chief Accounting Officer/General Counsel
David Nassif
Other
Gavin Corcoran
Lead Director/Independent Director
Atul Pande
Director
Eric Venker
Independent Director
Berndt Modig
Independent Director
Senthil Sundaram
Independent Director
Kristiina Vuori
No Data
No Data
About SIOX
Sio Gene Therapies Inc. is a clinical-stage company. The Company is focused on developing gene therapies for neurodegenerative diseases. The Company is developing a pipeline of product candidates for the treatment of these debilitating diseases, including GM1 gangliosidosis, GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, and Parkinson's disease. The Company is under three clinical-stage programs, AXO-AAV-GM1, AXO-AAV-GM2 and AXO-Lenti-PD. The AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis. The program utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the GLB1 gene. The AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases. The AXO-AAV-GM2 program utilizes dual AAV vectors to deliver functional copies of both the HEXA gene and the HEXB gene. The AXO-Lenti-PD program for the treatment of Parkinson's disease, comprised of the ProSavin Phase 0.5 study.

Webull offers kinds of Sio Gene Therapies Inc stock information, including NASDAQ:SIOX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SIOX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SIOX stock methods without spending real money on the virtual paper trading platform.